Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | AB928 + Enzalutamide + Zimberelimab |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
AB928 | AB 928|AB-928|Etrumadenant | Adenosine Targeting 19 | AB928 (etrumadenant) is an antagonist of the adenosine receptors A2aR and A2bR, which may relieve adenosine-mediated immune suppression and lead to enhanced anti-tumor activity in combination with other agents (European Journal of Cancer, Vol 92, S14-S15, PMID: 30569245). | |
Enzalutamide | Xtandi | MDV3100|ASP9785 | Hormone - Anti-androgens 38 | Xtandi (enzalutamide) is a second-generation small molecule androgen receptor (AR) inhibitor that inhibits AR signaling, thereby resulting in decreased tumor growth (PMID: 24009414, PMID: 25945058). Xtandi (enzalutamide) is FDA approved for use in patients with castration-resistant prostate cancer and metastatic hormone-sensitive prostate cancer (FDA.gov). |
Zimberelimab | GLS-010|AB122|AB-122|GLS010 | Immune Checkpoint Inhibitor 147 PD-L1/PD-1 antibody 87 | Zimberelimab (GLS-010) is a monoclonal antibody that targets PD-1 (PDCD1) and inhibits binding of the PD-L1 (CD274) ligand, potentially resulting in enhanced anti-tumor immune response (PMID: 28679395). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04381832 | Phase Ib/II | AB928 + Enzalutamide + Zimberelimab AB928 + Docetaxel + Zimberelimab AB680 + AB928 + Zimberelimab AB680 + AB928 Enzalutamide Docetaxel AB928 + Zimberelimab | Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer (ARC-6) | Recruiting | USA | CAN | 0 |